FibroBiologics, Inc. Common Stock beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.93 | $-0.66 | +29.0% | Beat |
| Q12026 FY2026 | $-1.26 | $-1.33 | -5.6% | Miss |
| Q42025 FY2025 | $-0.09 | $-0.03 | +66.7% | Beat |
Back to FBLG overview · FBLG holders · FBLG KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.